EnChuKong hospital
New Taipei City, Sanxia Dist, 237, Taiwan
NCT Number: NCT03532789
Overactive bladder is a clinical syndrome characterized by frequency, with or without urge incontinence, urgency, and nocturia, which affect patients' sleeping quality and rehabilitation program progressing. Current treatments include behavioral therapy (eg, life style adjustment, bladder training, pelvic floor muscle therapy) and medication. Antimuscarinic agents is the most common medications prescribed for OAB, but patients often have side effects like dry mouth and constipation. And there were plenty of herbal medicine which are beneficial to urine frequency and voiding dysfunction in ancient Chinese medicine books and records. In human trial, 62 Subjects diagnosed as overactive bladder will be enrolled and treated with Cinnamon patch. After treatment we will estimate the efficacy and record adverse events to conduct statistically analysis.
Looking for future studies?
Notify Me20 year and older
All sexes
Interventional
Phase 2 / Phase 3
New Taipei City, Sanxia Dist, 237, Taiwan
Overactive bladder is a clinical syndrome characterized by frequency, with or without urge incontinence, urgency, and nocturia, which affect patients' sleeping quality and rehabilitation program progressing. Current treatments include behavioral therapy (eg, life style adjustment, bladder training, pelvic floor muscle therapy) and medication. Antimuscarinic agents is the most common medications prescribed for OAB, but patients often have side effects like dry mouth and constipation. And there were plenty of herbal medicine which are beneficial to urine frequency and voiding dysfunction in ancient Chinese medicine books and records. In human trial, 62 Subjects diagnosed as overactive bladder will be enrolled and treated with Cinnamon patch. After treatment we will estimate the efficacy and record adverse events to conduct statistically analysis.
The 1st year project: (1) Expect to enroll 62 clinical subjects of OAB. (2) Evaluate subjects 'symptom and proceed patch treatment. (3) Record treatment responses including adverse effect. (4) Conduct statistically analysis.
The 2nd year project: (1) Completing enrollment of 62 clinical subjects of OAB. (2) Finish evaluation and treatment of all subjects. (3) Statistically analysis all collecting data (4) Discuss and analyze the outcome.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
One patch with medicine should be applied to the skin every other day within two weeks
Other names: OAB patch
One patch without medicine should be applied to the skin every other day within two weeks
Other names: control patch
Time frame: Change from Baseline OABSS at 2weeks
Overactive bladder symptom score, questionnaire
Time frame: Change from Baseline PPBC at 2weeks
Patient perception of bladder condition, questionnaire
Time frame: Change from Baseline USS at 2weeks
Urgency Severity Scale, questionnaire
Time frame: Change from Baseline TCMBCQ at 2weeks
Traditional Chinese Medicine Body Constitution Questionnaire
En Chu Kong Hospital
Other
Clinical Evaluation of Herbal Patch for Overactive Bladder Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06170450
Overactive Bladder Syndrome
Louisville, Kentucky, United States
View Trial DetailsNCT06389838
Female Urinary Stress Incontinence, Female Urogenital Diseases
Mainz, Germany
View Trial DetailsNCT06198439
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Houston, Texas, United States
View Trial DetailsNCT05308979
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Orange, California, United States
View Trial Details